Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Shares of Kura Oncology KURA have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, ...